
Pyxis Oncology, Inc.: updates and filings
Price
$1.81
November 20, 2026Market cap $216M
What Ploutos Investor adds for Pyxis Oncology
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 9, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
September 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 19, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Amended articles or bylaws, shareholder voteForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Nov 3, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 21, 2026Annual meeting proxy statementFormDEF 14A
- Oct 9, 2026Preliminary proxy statementFormPRE 14A
- Oct 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 5, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 2, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 1, 2026Material agreement entered, other material eventsForm8-K
- Sep 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 8, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 27, 2026FilingFormEFFECT
- Aug 20, 2026Shelf registration for future offeringsFormS-3
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 2, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosureForm8-K
- Jul 2, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 15, 2026Shareholder voteForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 19, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | 8-K | Amended articles or bylaws, shareholder vote | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 3, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 9, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Oct 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 5, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 2, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 1, 2026 | 8-K | Material agreement entered, other material events | Document |
| Sep 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 8, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 27, 2026 | EFFECT | Filing | Document |
| Aug 20, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 2, 2026 | 8-K | Material agreement entered, unregistered sale of shares, Regulation FD disclosure | Document |
| Jul 2, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 15, 2026 | 8-K | Shareholder vote | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 12, 2019.
The full analysis
What do Pyxis Oncology's filings show?
The filings are where every one of Pyxis Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.